Grandview Asset Management LLC bought a new stake in shares of Clorox Co (NYSE:CLX) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 2,697 shares of the company’s stock, valued at approximately $416,000.
Other institutional investors and hedge funds have also bought and sold shares of the company. Meeder Asset Management Inc. purchased a new position in shares of Clorox during the fourth quarter valued at approximately $26,000. City Holding Co. increased its stake in shares of Clorox by 150.0% during the fourth quarter. City Holding Co. now owns 250 shares of the company’s stock valued at $39,000 after buying an additional 150 shares during the period. G&S Capital LLC increased its stake in shares of Clorox by 46.4% during the fourth quarter. G&S Capital LLC now owns 262 shares of the company’s stock valued at $40,000 after buying an additional 83 shares during the period. Sonora Investment Management LLC purchased a new position in shares of Clorox during the fourth quarter valued at approximately $50,000. Finally, Ipswich Investment Management Co. Inc. purchased a new position in shares of Clorox during the fourth quarter valued at approximately $73,000. 82.60% of the stock is currently owned by hedge funds and other institutional investors.
Shares of CLX stock opened at $155.70 on Monday. The firm has a market capitalization of $19.95 billion, a P/E ratio of 24.87, a PEG ratio of 3.86 and a beta of 0.29. Clorox Co has a twelve month low of $113.57 and a twelve month high of $167.70. The company has a debt-to-equity ratio of 3.08, a quick ratio of 0.66 and a current ratio of 1.15.
Clorox (NYSE:CLX) last issued its quarterly earnings results on Monday, February 4th. The company reported $1.40 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.32 by $0.08. The company had revenue of $1.47 billion for the quarter, compared to analysts’ expectations of $1.47 billion. Clorox had a return on equity of 105.97% and a net margin of 12.65%. The firm’s revenue for the quarter was up 4.0% on a year-over-year basis. During the same period in the prior year, the firm earned $1.77 earnings per share. As a group, equities analysts anticipate that Clorox Co will post 6.33 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Friday, February 8th. Investors of record on Wednesday, January 23rd were paid a $0.96 dividend. The ex-dividend date of this dividend was Tuesday, January 22nd. This represents a $3.84 annualized dividend and a yield of 2.47%. Clorox’s payout ratio is 61.34%.
In other Clorox news, SVP Michael R. Costello sold 6,882 shares of the business’s stock in a transaction on Thursday, November 15th. The stock was sold at an average price of $160.08, for a total value of $1,101,670.56. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Matthew T. Laszlo sold 10,585 shares of the business’s stock in a transaction on Wednesday, February 6th. The stock was sold at an average price of $153.89, for a total value of $1,628,925.65. Following the completion of the sale, the senior vice president now directly owns 17,994 shares in the company, valued at $2,769,096.66. The disclosure for this sale can be found here. Insiders sold 256,728 shares of company stock worth $41,973,324 over the last three months. Corporate insiders own 1.40% of the company’s stock.
Several research firms have recently issued reports on CLX. Zacks Investment Research raised Clorox from a “sell” rating to a “hold” rating in a research note on Monday, December 10th. Citigroup set a $171.00 price target on Clorox and gave the stock a “hold” rating in a research note on Tuesday, February 5th. Wells Fargo & Co reaffirmed a “hold” rating and issued a $157.00 price target on shares of Clorox in a research note on Monday, February 4th. Bank of America reaffirmed a “neutral” rating and issued a $170.00 price target (up from $150.00) on shares of Clorox in a research note on Thursday, December 6th. Finally, Barclays reaffirmed a “hold” rating and issued a $142.00 price target on shares of Clorox in a research note on Wednesday, February 6th. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $149.08.
WARNING: This story was published by Fairfield Current and is owned by of Fairfield Current. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://www.fairfieldcurrent.com/news/2019/02/11/grandview-asset-management-llc-buys-new-position-in-clorox-co-clx.html.
Clorox Company Profile
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.
Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clorox Co (NYSE:CLX).
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.